The Truth About Lymphopenia Therapeutics Market Is About To Be Revealed

Posted by Loise Williams on October 23rd, 2019

The global lymphopenia therapeutics market is expected to grow at a CAGR of 3.96% during the forecast period. Based on the product, the market has been segmented into Acquired lymphopenia and inherited lymphopenia. As per the latest market research report published by Technavio, the global lymphopenia therapeutics market has the potential to grow by USD 392.51 million during 2019-2023, and the market's growth momentum will accelerate throughout the forecast period. Get the free sample report below for the detailed information.

Download the free sample report @ http://bit.ly/2MCzD2E

The acquired lymphopenia segment has various therapy areas, including infectious diseases, autoimmune disorders, blood cancer, and other blood diseases, and therapies such as steroid, radio, and chemotherapy. The rising incidence of diseases from these therapy areas is expected to drive the growth of this segment during the forecast period. 

The approval of the drugs for treating underlying causes of lymphopenia contribute to the growth of lymphopenia therapeutics market in this segment. In April 2019, ViiV Healthcare Ltd. received the US FDA approval for DOVATO, the first, once-daily, single-tablet, two-drug regimen for the treatment-naïve HIV-1 adult patients without antiretroviral treatment history. Furthermore, in November 2018, Seattle Genetics Inc. received the US FDA approval for ADCETRIS in combination with cyclophosphamide, doxorubicin, and prednisone chemotherapy for adult patients with previously untreated systematic anaplastic large cell lymphoma.